中西医协同防治青少年近视的临床研究

注册号:

Registration number:

ITMCTR2025000821

最近更新日期:

Date of Last Refreshed on:

2025-04-22

注册时间:

Date of Registration:

2025-04-22

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

中西医协同防治青少年近视的临床研究

Public title:

Clinical Study on the Prevention and Control of Myopia in Adolescents by Combining Traditional Chinese and Western medicine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中西医协同防治青少年近视的临床研究

Scientific title:

Clinical Study on the Prevention and Control of Myopia in Adolescents by Combining Traditional Chinese and Western medicine

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曹姚佳妮

研究负责人:

周行涛

Applicant:

Cao Yaojiani

Study leader:

Zhou Xingtao

申请注册联系人电话:

Applicant telephone:

13564739117

研究负责人电话:

Study leader's telephone:

13816880725

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

caoyaojiani@163.com

研究负责人电子邮件:

Study leader's E-mail:

doczhouxingtao@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区汾阳路83号

研究负责人通讯地址:

上海市徐汇区汾阳路83号

Applicant address:

NO.83 Fenyang Road Xuhui district Shanghai

Study leader's address:

NO.83 Fenyang Road Xuhui district Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属眼耳鼻喉科医院

Applicant's institution:

Eye & ENT Hospital Fudan University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

[2024]伦审字第(2024030-1)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

复旦大学附属眼耳鼻喉科医院伦理委员会

Name of the ethic committee:

Ethics Committee of Eye & ENT Hospital Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2024/4/19 0:00:00

伦理委员会联系人:

闫晶超

Contact Name of the ethic committee:

Yan Jingchao

伦理委员会联系地址:

上海市徐汇区汾阳路83号

Contact Address of the ethic committee:

No.83 Fenyang Road Xuhui District Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

021-64377134

伦理委员会联系人邮箱:

Contact email of the ethic committee:

fdeent_ec@126.com

研究实施负责(组长)单位:

复旦大学附属眼耳鼻喉科医院

Primary sponsor:

Eye & ENT Hospital Fudan University

研究实施负责(组长)单位地址:

上海市徐汇区汾阳路83号

Primary sponsor's address:

NO.83 Fenyang Road Xuhui district Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属眼耳鼻喉科医院

具体地址:

上海市徐汇区汾阳路83号

Institution
hospital:

Eye & ENT Hospital Fudan University

Address:

NO.83 Fenyang Road Xuhui district Shanghai

经费或物资来源:

综合医院中西医协同引导项目(ZXXT-202307)

Source(s) of funding:

Collaborative guidance of traditional Chinese and western medicine in general hospital (ZXXT-202307)

研究疾病:

近视

研究疾病代码:

Target disease:

Myopia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究拟采用随机、平行、对照的研究设计,通过观察青少年近视人群治疗前后眼轴长度、等效球镜度、裸眼视力、前房深度、晶体厚度、调节滞后量、脉络膜厚度、脉络膜血流等指标变化,客观评估中西医协同防治青少年近视的临床疗效,并探索其可能的机制。

Objectives of Study:

This randomized parallel and controlled study was designed to observe the changes of axial length spherical equivalent uncorrected visual acuity anterior chamber depth lens thickness accommodative lag choroidal thickness and choroidal blood flow before and after treatment and to objectively evaluate the clinical efficacy of integrated traditional Chinese and western medicine in the prevention and treatment of juvenile myopia and to explore its possible mechanism.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.年龄在7至14岁之间; 2.符合单纯性近视诊断标准:在常态调节下远距离视物模糊,近距离视力好;检影为近视性屈光不正,通过负球镜片(或加负柱镜片)进行远视力矫正可达正常;近视程度较低;其余眼部视功能基本正常; 3.睫状肌麻痹后的屈光度数:-0.50D<SE≤-3.00D; 4.自愿加入研究,依从性良好,监护人签订知情同意书。

Inclusion criteria

1.Patients aged 7-14 years; 2.Patients meet the diagnostic criteria of simple myopia: blurred distant vision under normal adjustment good near-distance vision; the image is myopic ametropia which can be corrected by negative spherical lens (or with negative column lens). The degree of myopia is low; The visual function of other eyes is basically normal; 3.Patients' diopter number after ciliary muscle paralysis: -0.50D < SE≤-3.00D; 4.Patients participate in the study voluntarily with good compliance and their guardian signed the informed consent.

排除标准:

1.合并有其他眼部疾病(白内障、先天性视网膜疾病、斜视、弱视等)和全身系统性疾病; 2.眼部活动性病变或眼科手术者; 3.对阿托品过敏者; 4.局部穴位皮肤破损、炎症及胶布过敏者; 5.监护人持有不合理期望。

Exclusion criteria:

1. Patients combined with other eye diseases (cataract congenital retinal disease strabismus amblyopia etc.) and systemic diseases; 2. Patients with active eye lesions or eye surgery; 3. Patients are allergic to atropine; 4. Patients with local acupoint skin damage inflammation and tape allergy; 5. The guardian has unreasonable expectations.

研究实施时间:

Study execute time:

From 2023-12-01

To      2025-11-30

征募观察对象时间:

Recruiting time:

From 2024-04-20

To      2025-02-28

干预措施:

Interventions:

组别:

中西医结合治疗组1

样本量:

30

Group:

Integrated Traditional Chinese and Western medicine treatment group 1

Sample size:

干预措施:

揿针联合0.01%阿托品滴眼液

干预措施代码:

Intervention:

Thumb-tack needle combined with 0.01% atropine eye drops

Intervention code:

组别:

中西医结合治疗组2

样本量:

30

Group:

Integrated Traditional Chinese and Western medicine treatment group 2

Sample size:

干预措施:

耳穴贴压联合0.01%阿托品滴眼液

干预措施代码:

Intervention:

Auricular acupressure combined with 0.01% atropine eye drops

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

0.01%阿托品滴眼液

干预措施代码:

Intervention:

0.01% atropine eye drops

Intervention code:

组别:

中西医结合治疗组3

样本量:

30

Group:

Integrated Traditional Chinese and Western medicine treatment group 3

Sample size:

干预措施:

揿针、耳穴贴压联合0.01%阿托品滴眼液

干预措施代码:

Intervention:

Thumb-tack needle and auricular acupressure combined with 0.01% atropine eye drops

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属眼耳鼻喉科医院

单位级别:

三级甲等

Institution/hospital:

Eye & ENT Hospital of Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

眼轴长度

指标类型:

主要指标

Outcome:

Axial length

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脉络膜血流

指标类型:

次要指标

Outcome:

Choroidal blood flow

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

裸眼视力

指标类型:

次要指标

Outcome:

Uncorrected visual acuity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

等效球镜度

指标类型:

主要指标

Outcome:

Spherical equivalent

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视网膜血流

指标类型:

次要指标

Outcome:

Retinal blood flow

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

晶体厚度

指标类型:

次要指标

Outcome:

Len thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脉络膜厚度

指标类型:

次要指标

Outcome:

Choroidal thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视网膜厚度

指标类型:

次要指标

Outcome:

Retinal thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

前房深度

指标类型:

次要指标

Outcome:

Anterior chamber depth

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 7
Min age years
最大 14
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计师采用区组随机化方法产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

The statistician uses block randomization method to generate random sequences.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

以论文发表形式公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Original data will be published in paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and an electronic data capture

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统